Dec 19, 2024
News
At NGM, we pride ourselves on conducting world-class science and sharing our research efforts with the broader scientific and medical communities.
Jul 17, 2024
NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum
Apr 05, 2024
NGM Bio Announces Closing of Tender Offer
Mar 19, 2024
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
Mar 11, 2024
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
Feb 26, 2024
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
Feb 20, 2024
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
Jan 17, 2024
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
Jan 09, 2024